FDA Approves Baraclude (entecavir) for Chronic Hepatitis B

29 March 2005 - Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved the oral antiviral drug BARACLUDE (entecavir) for the treatment of chronic hepatitis B infection in adults. The drug will be available in the United States as early as April 8, 2005. Read Full Article